Updates on COVID-19 (including visitor restrictions and mask requirements), monkeypox and flu. See Communicable Disease Updates

Your browser is out-of-date!

Internet Explorer 11 has been retired by Microsoft as of June 15, 2022. To get the best experience on this website, we recommend using a modern browser, such as Safari, Chrome or Edge.

×

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Trial ID:
IRB-22-7924
Darren Sigal, M.D.
This study will test the safety and effectiveness of OBI-3424. OBI-3424 is an investigational study drug given once every three weeks via intravenous (IV) infusion in patients with advanced solid tumor cancer. This is the first study using OBI-3424 in humans.

Inclusion Criteria

Patients must:
  • Be 18 years of age or older.
  • Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light housework or office work.
  • Have tumor tissue collected from a previous or new biopsy to be submitted for eligibility analysis

Exclusion Criteria

Patients must not:
  • Be pregnant or nursing.
  • Have hepatocellular carcinoma.
  • Have a history of symptomatic brain disease.
  • Have had prior radiotherapy to more than 25% of the bone marrow.

Additional Info

  • All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (Geisel Pavilion).
  • Participation in the study will last for up to 2 years.
  • Search for NCT03592264 on https://clinicaltrials.gov/ for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org